Delving into the Latest Updates on YZ-002 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Immune System Diseases

Active Indication

Autoimmune Diseases

Inactive Indication-

Originator Organization

Guangdong Yinzhu Pharmaceutical Technology Co., Ltd.

Active Organization

Guangdong Yinzhu Pharmaceutical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

AIMTo analyze YZ-2, a novel protein associated with cerebral ischemia and prepares its polyclonal antibody.METHODSAccording to the bioinformatics analysis and prediction of the possible high structure, hydrophilicity and antigenicity of YZ-2, a 22-amino acid residue partial peptide of YZ-2 was synthesized. The synthesized peptide was then used to immunize. And the properties of anti-YZ2 were analyzed by ELISA and Western blot.RESULTSThe hydrophilicity and antigenicity were predicted by methods of bioinformatics. The polyclonal antibody of YZ-2 was successfully obtained and its specificity and sensitivity were conformed by ELISA and Western blot.CONCLUSIONBy the bioinformatics analysis and prediction, the hydrophilicity and antigenicity of YZ2 were analyzed. The antibody of YZ-2 was successfully obtained.

RSC AdvancesQ3 · CHEMISTRY

Optimization and characterization of biosurfactant produced by indigenous Brevibacillus borstelensis isolated from a low permeability reservoir for application in MEOR

Q3 · CHEMISTRY

ArticleOA

Author: Li, Yang ; She, Yuehui ; Wang, Xiaotong ; Gu, Yongan ; He, Yanlong ; Dong, Hao ; Banat, I. M. ; Zheng, Anying ; Yu, Gaoming ; Sun, Shanshan ; Zhang, Fan

Biosurfactants are expected to be a key factor for microbial enhanced oil recovery (MEOR).

100 Deals associated with YZ-002

Login to view more data